HC Wainwright reiterates Buy on Corcept Therapeutics, $165 target
HC Wainwright & Co. reiterated a Buy rating on Corcept Therapeutics and set a $165.00 price target, implying 43.7% upside versus the Sep 17 close of $114.86.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.